Cargando…

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases

In the present study we evaluated how systemic arterial hypertension (SAH), dyslipidemia and diabetes mellitus influence the efficacy, safety and retention rate of biological disease-modifying anti-rheumatic drug (bDMARD) treatment in rheumatic musculoskeletal disorders (RMDs). The charts of RMD pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cometi, Laura, Bruni, Cosimo, Chiti, Nicolò, Tofani, Lorenzo, Nacci, Francesca, Bartoli, Francesca, Bellando-Randone, Silvia, Melchiorre, Daniela, Fiori, Ginevra, Guiducci, Serena, Matucci-Cerinic, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290363/ https://www.ncbi.nlm.nih.gov/pubmed/32370139 http://dx.doi.org/10.3390/jcm9051310

Ejemplares similares

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience
por: Cometi, Laura, et al.
Publicado: (2020)

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life
por: El Aoufy, Khadija, et al.
Publicado: (2021)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide
por: Borghini, Annalisa, et al.
Publicado: (2015)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
por: Bruni, Cosimo, et al.
Publicado: (2018)

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
por: Mazzotta, Celestina, et al.
Publicado: (2015)

Interstitial lung disease in systemic sclerosis: where do we stand?
por: Cappelli, Susanna, et al.
Publicado: (2015)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
por: Bargagli, Elena, et al.
Publicado: (2019)

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review
por: Bonomi, Francesco, et al.
Publicado: (2022)

The Emerging Challenge of Pain in Systemic Sclerosis: Similarity to the Pain Experience Reported by Sjőgren’s Syndrome Patients
por: De Luca, Rossella, et al.
Publicado: (2021)

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
por: Fiorentini, Elisa, et al.
Publicado: (2022)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
por: Peretti, Silvia, et al.
Publicado: (2022)

Systemic Sclerosis Patients Experiencing Mindfulness-Based Stress Reduction Program: The Beneficial Effect on Their Psychological Status and Quality of Life
por: El Aoufy, Khadija, et al.
Publicado: (2023)

Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis
por: Manetti, Mirko, et al.
Publicado: (2017)

Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence
por: Manetti, Mirko, et al.
Publicado: (2019)

Menstruation-Related Disorders—Dysmenorrhea and Heavy Bleeding—as Significant Epiphenomena in Women With Rheumatic Diseases
por: Orlandi, Martina, et al.
Publicado: (2022)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

Rehabilitation of the face and temporomandibular joint in systemic sclerosis
por: Maddali Bongi, Susanna, et al.
Publicado: (2021)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach
por: Bellando-Randone, Silvia, et al.
Publicado: (2021)

The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis
por: Avanoǧlu Güler, Aslıhan, et al.
Publicado: (2020)

Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis
por: Rosa, Irene, et al.
Publicado: (2023)

Temporomandibular joint involvement (TMJ), a silent disease with severe alterations in young adulthood patients affected by juvenile idiophatic arthritis (JIA)
por: Fernanda, Falcini, et al.
Publicado: (2011)

Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS)
por: Mavrogeni, Sophie, et al.
Publicado: (2020)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Pathophysiology of Hemophilic Arthropathy
por: Melchiorre, Daniela, et al.
Publicado: (2017)

Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide
por: Villano, Marilisa, et al.
Publicado: (2013)

Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
por: Bandinelli, Francesca, et al.
Publicado: (2016)

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
por: Blagojevic, J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fav8sbdi8o9cguimf3dn48dcpe